Northern Gritstone led the seed round with backing from Finance Yorkshire and NPIF II, Praetura Equity Finance to fund team expansion and product development.
"The robotics market is growing fast, but that growth would be exponentially higher if the tremendous cost and complexity of programming robots were reduced. Robotics has an almost unlimited potential to help humanity solve global challenges, but the world simply can’t afford to wait for robotics to standardise around a single operating system and coding language. BOW’s universal software platform and SDK elegantly solve this intractable problem by enabling any software developer to program various types of robots using the coding language of their choice, make portable applications and enable easy interoperability between any make and model of robot. This £4 million seed investment, led by Northern Gritstone, will be used to build on our strong commercial traction to date, expand our brilliant team and accelerate our product development so we can unleash the full potential of robotics for the betterment of our world."
Northern Gritstone leads Series A round into the Manchester-based manufacturing technology platform.
"Northern Gritstone is delighted to support Partful. This growing Manchester-based tech company has already won large OEM customers thanks to its technology and is set to create more jobs in its North of England team"
Northern Gritstone led the over-subscribed seed round with participation from Empirical Ventures, Praetura Ventures, and private backers.
"Northern Gritstone is delighted to support Exciting Instruments’ internationally renowned team from the University of Sheffield. Their technology will open up a broad range of health-related research and discovery and will also support job creation in Sheffield’s thriving tech cluster."
Northern Gritstone led the seed extension round, which included participation from ACF Investors, Empirical Ventures, Deeptech Labs, and Hamamatsu Ventures.
"The progress made by the Silveray team since our initial investment in 2023 has been phenomenal. Dan Cathie and his team have the enviable combination of innovation and entrepreneurialism having developed a novel digital x-ray solution with numerous applications which are already disrupting the analogue x-ray market. We are delighted to continue our support of Silveray as it builds its commercial traction, helping the team on its path to success."
The equity round was led by EQT Life Sciences and Sectoral to support international expansion and clinical trials.
"Dysphagia is a severe medical condition that affects countless patients in hospital. It can increase hospital length of stay, the risk of complications, and lengthens recovery time. The Phagenyx System demonstrates significant reductions in hospital length of stay, with a corresponding and substantial reduction in healthcare costs, as evidenced by the Company’s strong portfolio of high-quality clinical studies. This is strongly aligned with EQT’s Health Economics strategy of transforming cutting-edge scientific innovation into impactful and cost-effective healthcare solutions. We‘re excited to support the next phase of Phagenesis’ journey."
